Laboratory of Neurodegenerative Diseases, Center for Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Laboratory of Neurodegenerative Diseases, Center for Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
Brain Res. 2021 Nov 15;1771:147639. doi: 10.1016/j.brainres.2021.147639. Epub 2021 Sep 4.
Parkinson's disease (PD) is the second most common neurodegenerative disease, comprised of both familial and idiopathic forms, behind only Alzheimer's disease (AD). The disease is characterized, regardless of the pathogenesis, primarily by a loss of DA neurons in the ventral midbrain as well as noradrenergic neurons of the locus coeruleus; however, by the time symptoms manifest, considerable neuronal loss in both areas has occurred. Neuroprotective strategies thus have to be paired with more sensitive and specific biomarker assays that can identify early at-risk patients in order to initiate disease-modifying therapies at an earlier stage in the disease. Complicating this is the fact that multiple forms of cell death mediate the neuronal loss; however, with a common underlying element that the cell death is considered a "regulated" form of cell death, in contrast to an un-controlled necrotic cell death process. In this review we focus our discussion on several categories of regulated cell death in the context of PD: apoptosis, necroptosis, pyroptosis, and autophagic cell death. In clinical studies as well as experimental in vivo models of PD, there is evidence for a role of each of these forms of cell death in the loss of midbrain DA neurons, and specific therapeutic strategies have been proposed and tested. What remains unclear however is the relative contributions of these distinct forms of cell death to the overall loss of DA neurons, whether they occur at different stages of the disease, or whether specific sub-regions within the midbrain are more susceptible to specific death triggers and pathways.
帕金森病(PD)是第二常见的神经退行性疾病,包括家族性和特发性形式,仅次于阿尔茨海默病(AD)。无论发病机制如何,该疾病的特征主要是腹侧中脑中 DA 神经元和蓝斑中的去甲肾上腺素能神经元丧失;然而,到症状出现时,这两个区域的神经元已经大量丧失。因此,神经保护策略必须与更敏感和更特异的生物标志物检测方法相结合,以便在疾病的早期阶段识别出有风险的早期患者,从而启动疾病修饰治疗。使情况复杂化的是,多种形式的细胞死亡介导神经元丧失;然而,有一个共同的潜在因素是细胞死亡被认为是一种“受调控”的细胞死亡形式,与不受控制的坏死性细胞死亡过程形成对比。在这篇综述中,我们将讨论 PD 背景下几种类型的受调控细胞死亡:细胞凋亡、坏死性细胞凋亡、细胞焦亡和自噬性细胞死亡。在临床研究以及 PD 的实验性体内模型中,有证据表明这些细胞死亡形式中的每一种都在中脑 DA 神经元丧失中发挥作用,并且已经提出并测试了特定的治疗策略。然而,目前尚不清楚这些不同形式的细胞死亡对 DA 神经元总体丧失的相对贡献,它们是否发生在疾病的不同阶段,或者中脑的特定亚区是否更容易受到特定的死亡触发因素和途径的影响。